Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides-Reference-Cited by-同舟云学术

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides

Published:2007-10-01 Issue:3 Volume:139 Page:415-424
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Curti Antonio,Tosi Patrizia,Comoli Patrizia,Terragna Carolina,Ferri Elisa,Cellini Claudia,Massaia Massimo,D’Addio Alessandra,Giudice Valeria,Di Bello Cristiana,Cavo Michele,Conte Roberto,Gugliotta Gabriele,Baccarani Michele,Lemoli Roberto M.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2007.06832.x/fullpdf

Reference34 articles.

1. Dendritic cells and the control of immunity;Bancherau;Nature,1998

2. Autologous lymphoma vaccines induce human T-cell responses against multiple unique epitopes;Baskar;Journal of Clinical Investigation,2004

3. Antitumor vaccination: where we stand;Bocchia;Haematologica,2000

4. Peripheral T-cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma;Bogen;European Journal of Immunology,1996

5. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta 1 and interleukin-10;Brown;Blood,2001

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and challenges in anti-cancer vaccines for multiple myeloma;Frontiers in Immunology;2024-08-01

2. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties;International Journal of Molecular Sciences;2024-05-22

3. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy;International Journal of Hematology;2023-03-25

4. Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions;International Journal of Molecular Sciences;2022-01-14

5. The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy;Molecular Cancer Therapeutics;2021-10-19